• 1
    Drossman DA, Camileri M, Mayer EA et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 210831.
  • 2
    Thompson WG, Longstreth GF, Drossman DA et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl. 2): 11437.
  • 3
    Quigley EMM, Bytzer P, Jones R et al. Irritable bowel syndrome: the burden and unmet needs in Europe. Dig Liv Dis 2006; 38: 71723.
  • 4
    Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994; 107: 27193.
  • 5
    McLean PG, Borman RA, Lee K. 5-HT in the enteric nervous system: gut function and neuropharmacology. Trends Neurosci 2007; 30: 913.
  • 6
    Charney DS. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 1998; 59: 114.
  • 7
    MacDonald AJ, Bouchier IAD. Non-organic gastrointestinal illness: a medical and psychiatric study. Br J Psychiatry 1980; 136: 27683.
  • 8
    Corney RH, Stanton R. Physical symptom severity, psychological and social dysfunction in a series of outpatients with irritable bowel syndrome. J Psychosom Res 1990; 34: 48391.
  • 9
    Irwin C, Falsetti SA, Lydiard RB et al. Comorbidity of posttraumatic stress disorder and irritable bowel syndrome. J Clin Psychiatry 1996; 57: 5768.
  • 10
    Blanchard EB, Scharff L, Schwartz SP et al. The role of anxiety and depression in the irritable bowel syndrome. Behav Res Ther 1990; 28: 4015.
  • 11
    Craig TKJ, Brown GW. Goal frustration and life events in the aetiology of painful gastrointestinal disorder. J Psychosom Res 1984; 28: 41121.
  • 12
    Bender DA. The relative importance of dietary tryptophan and performed nicotinic acid and nicotinamide as precursors of nicotinamide nucleotide coenzymes. In: BenderDA, JosephMH, KochenW, SteinhartHW, eds. Progress in Tryptophan and Serotonin Research. Berlin: de Gruyter, 1986: 15964.
  • 13
    Wirleitner B, Neutauter G, Schrocksnadel K et al. Interferon-γ-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem 2003; 10: 158191.
  • 14
    Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 1994; 40: 28895.
  • 15
    Widner B, Laich A, Sperner-Unterweger B et al. Neopterin production tryptophan degradation and mental depression: what is the link? Brain Behav Immun 2002; 16: 5905.
  • 16
    Coates MD, Mahoney CR, Linden DR et al. Molecular defects in mucosal serotoinin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126: 165764.
  • 17
    Miwa J, Echizen H, Matsueda K et al. Patients with constipation predominant irritable bowel syndrome may have elevated serotonin concentrations in colonic mucosa as compared with diarrhea-predominant patients and subjects with normal bowel habits. Digestion 2001; 63: 18894.
  • 18
    Wollny T, Rydzewska G, Pawlak D et al. Kynurenic pathway metabolites in serum of patients with irritable bowel syndrome – possible role in the mechanism of visceral pain. Gastroenterol Pol 2006; 13: 15962.
  • 19
    Dinan TG, Quigley EMM, Ahmed SMM et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006; 130: 30411.
  • 20
    O’Mahony L, McCarthy J, Kelly P et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 54151.
  • 21
    Liebregts T, Adam B, Bredack C et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 91320.
  • 22
    Schrocksnadel K, Wirleitner B, Winkler C et al. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 2006; 364: 8290.
  • 23
    Spitzer RL, Kroenke K, Williams JBW. Validation and utility of a self-report version of PRIME-MD. The PHQ Primary Care Study. JAMA 1999; 282: 173744.
  • 24
    Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16: 60613.
  • 25
    Van der Horst HE, Van Dulmen AM, Schellevis FG et al. Do patients with irritable bowel syndrome in primary care really differ from outpatients with irritable bowel syndrome? Gut 1997; 41: 66974.
  • 26
    Bleijenberg G, Fennis JFM. Anamnestic and psychological features in diagnosis and prognosis of functional abdominal complaints: a prospective study. Gut 1989; 30: 107681.
  • 27
    Fennis JFM, Bleijenberg G, Hermans-van Wordragen R. Psychologic factors in diagnosis, prognosis, and treatment of functional abdominal complaints. Scand J Gastroenterol 1990; 25(Suppl. 178): 36.
  • 28
    Herve C, Beyne P, Jamault H et al. Determination of Tryptophan and it’s Kynurenine pathway metabolites in human serum by high-performance liquid chromatography with simultaneous ultraviolet and fluorimetric detection. J Chromatogr B, 1996; 675: 15761.
  • 29
    Delgado PL, Price LH, Miller HL et al. Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry 1994; 51: 86574.
  • 30
    Reilly JG, McTavish SF, Young AH. Rapid depletion of plasma tryptophan: a review of studies and experimental methodology. J Psychopharmcol 1997; 11: 38192.
  • 31
    Kent JM, Coplan JD, Martinez J et al. Ventilatory effects of tryptophan depletion in panic disorder: a preliminary report. Psychiatry Res 1996; 64: 8390.
  • 32
    Bell C, Abrams J, Nutt D. Tryptophan depletion and its implications for psychiatry. Br J Psychiatry 2001; 178: 399405.
  • 33
    Kilkens TO, Honig A, Van Nieuwenhoven MA et al. Acute tryptophan depletion affects brain-gut responses in irritable bowel syndrome patients and controls. Gut 2004; 53: 1794800.
  • 34
    Shufflebotham J, Hood S, Hendry J et al. Acute tryptophan depletion alters gastrointestinal and anxiety symptoms in irritable bowel syndrome. Am J Gastroenterol 2006; 101: 25827.
    Direct Link:
  • 35
    Shannon HE, Sawyer BD. Glutamate receptors of the NMDA subtype in myenteric plexus of the guinea pig ileum. J Pharmacol Exp Ther 1989; 215: 51823.
  • 36
    McRoberts JA, Coutinho SV, Marvizon JCG et al. Role of peripheral N-Methyl-D-Aspartate (NMDA) receptors in visceral nociception in rats. Gastroenterology 2001; 120: 173748.
  • 37
    Luzzi S, Zilletti S, Franchi-Micheli S et al. Agonists, antagonists and modulators of excitatory amino acid receptors in the guinea-pig myenteric plexus. Br J Pharmacol 1988; 95: 12717.
  • 38
    Forrest CM, Gould SR, Darlington LG et al. Levels of purine, kunurenine and lipid peroxidation products in patients with inflammatory bowel disease. In: AllegriG, CostaC, RegazziE, eds. Developments in Tryptophan and Serotonin Metabolism. New York: Kluwer Academic/Plenum, 2003: 395400.
  • 39
    Shirey KA, Jung JY, Maeder GS et al. Upregulation of IFN-gamma receptor expression of proinflammatory cytokines influences IDO activation in epithelial cells. J Interferon Cytokine Res 2006; 26: 5362.
  • 40
    Robinson CM, Shirey KA, Carlin JM. Synergistic transcription activation of indoleamine dioxygenase by IFN-gamma and tumor necrosis factor-alpha. J Interferon Cytokine Res 2003; 23: 41321.
  • 41
    Braun D, Longman RS, Albert ML. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 2005; 106: 237581.
  • 42
    Maes M, Scharpe S, Meltzer HY et al. Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res 1994; 54: 14360.
  • 43
    Myint AM, Kim YK, Verkerk R et al. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord 2007; 98(1–2): 14351.